Browse By: Country ι Category ι Tag
Home  »  La Merie Publishing

La Merie Publishing Market Research Reports

La Merie Publishing is an independent business information provider for the biopharmaceutical industry. We publish reports and newsletters, and provide the service of preparing tailor-made reports. The full range of our products are commercialized via our associated biotech portal PipelineReview.com and reselling partners.


The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities
The field of oncolytic viruses was quite dormant in the first decade of the 2000s, characterized by slow clinical progress due to hypercautiousness and low, albeit steady, investments. The takeover of BioVex by Amgen in late 2011, worth up to US$ 1 bln, has woken up the field and became a game changer together with the 2015 approval of the first oncolytic virus Imlygic developed by BioVex in regulated markets. In addition, it was increasingly recognized that oncolytic viruses not only were able to directly lyse cancer cells, but they also „freed“ tumor specific neoantigens, indirectly acting as a cancer vaccine.
Published Date: Jan 2017
Published By: La Merie Publishing

Price: $2400
Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company
The competitive intelligence report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ evaluates and describes the competitive landscape of antibody-drug conjugates (ADCs) in a tabular format by target, payload, R&D phase and company as of December 2016.
Published Date: Dec 2016
Published By: La Merie Publishing

Price: $834
Report Package: Hot targets for empowered antibody and cell therapy technologies
This package contains three reports analyzing BCMA, CD123 and CD22 as versatile and hot targets for the successful application of empowered antibody and cell technologies, including: Fc-Engineered Antibodies; Radioimmunotherapy;   Immunotoxins; Antibody-Drug Conjugates; T-Cell Redirecting Bispecific Antibodies; Chimeric Antigen Receptor (CAR) T-Cells. The reports describe and discuss Target background, scientific rationale & expression profiles; Preclinical proof-of-concept; Clinical experience; Competitive landscape; Drug or cell therapy profiles; Company profiles. Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices: B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities CD123:
Published Date: Dec 2016
Published By: La Merie Publishing

Price: $1254
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-B/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Others
This Competitive Intelligence report about Tumor Microenvironment Modulation via IDO, TGF-B/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Othersevaluates as of December 2016 the competitive field of mainly inhibitors and antagonists of substrates, enzymes and receptors involved in the immunosuppressive tumor microenvironment, including IDO (Indoleamine 2,3-dioxygenase TDO ( Tryptophan 2,3 dioxygenase) TGF-B/R ( Transforming Growth Factor beta/Receptor) CXCR4(Chemokine Receptor Type 4) CSF-1R ( Colony Stimulating Factor-1 Receptor) CD47 – SIRPa (Signal Regulatory Protein Alpha) Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine STING (STimulator of INterferon Genes) Receptor Others ( e.g. arginase) Purchase of
Published Date: Dec 2016
Published By: La Merie Publishing

Price: $770
Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology
This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC). Purchase of this product includes a 6-month online access to the data of the reports and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Each of the four reports can be obtained individ
Published Date: Dec 2016
Published By: La Merie Publishing

Price: $1386
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment modalities. In B-cell non-Hodkgina lymphoma (NHL), CD22 expression ranges from 91% to 99% in the aggressive and indolent populations, respectively. CD22 expression occurs in more than 90% of patients with B-lineage acute lymphoblastic leukemia (ALL). CD22 is not expressed on non-B lineage cells or hematopoietic stem cells.
Published Date: Nov 2016
Published By: La Merie Publishing

Price: $784
TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs
The report „TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs“ describes and analyzes the status of the adoptive cell therapy industry as of August 2016. The report covers autologous and allogeneic engineered chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapy candidates as well as natural killer (NK) cell and CAR engineered NK cells in research and development by biopharmaceutical companies. 
Published Date: Aug 2016
Published By: La Merie Publishing

Price: $2750
T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals
Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR). 
Published Date: May 2016
Published By: La Merie Publishing

Price: $2400
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update
This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target. 
Published Date: May 2016
Published By: La Merie Publishing

Price: $1450
Antibody Target, Technology & Pipeline Database: 1-Year Subscription
Therapeutic monoclonal antibodies have become a clinically and commercially successful class of drugs.
Published Date: Apr 2016
Published By: La Merie Publishing

Price: $1600
RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists
Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but difficult-to-drug target. More than 30 companies are active in drug discovery and development.
Published Date: Feb 2016
Published By: La Merie Publishing

Price: $1050
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis
Although the initial enthusiasm about antibody-drug conjugates has made room for a more realistic understanding, the prospects for success of ADC drug candidates remain good and are based on a well-filled pipeline, increasing adoption of next generation ADC technologies, lessons learned from failures, a balanced mixture of stakeholders and a variety of options for funding of ADC developments.
Published Date: Nov 2015
Published By: La Merie Publishing

Price: $2500
Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors
Competitor Analysis: Therapeutic Antibodies 2015: Biosimilars & Biosuperiors This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of April 2015. Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 82.2 bln (+8.6% vs previous year) in the year 2014. The report lists specifically for each target the branded products with their 2014 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development. The report
Published Date: Apr 2015
Published By: La Merie Publishing

Price: $1500
Engineered TCR and CAR Immunotherapeutics 2015
The engineered T cell receptor (TCR) for targeting of intracellular targets not druggable by conventional antibody technologies, and specifically targeted engineered T cells are two of the most promising emerging technologies in immuno-oncology apart from immune checkpoint modulators. The relevance of TCR targeting and engineered T cells is reflected by impressive clinical results with CD19 chimeric antigen receptor (CAR) T cells and outstanding partnering and financing deals concluded within the last two years. This report „Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs“ as of March 2015 brings you up-to-date regarding key players, k
Published Date: Mar 2015
Published By: La Merie Publishing

Price: $2630
Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants
This report provides an update of recombinant coagulation factors used for controlling bleeding of hemophilia A and B and other bleeding disorders. 2013 sales figures and 2014 nine-month sales data are analyzed to evaluate commercial development of the market under the light of a strong pipeline and entry of new competitor products into the market. The profiles of drug candidates in development are presented in details not only for recombinant coagulation factors VIII, IX and VII, but also for emerging alternative procoagulants, gene therapeutics and immune tolerance inducing agents. The competitve landscape of classical recombinant coagulation factors and of new emerging treatment modalities of hemophilia and other severe bleeding orders is analyzed. The emergence of new treatment moda
Published Date: Dec 2014
Published By: La Merie Publishing

Price: $2795
Peptide Therapeutics Pipeline Database: 1-Year Subscription
Subscription to La Merie Publishing’s proprietary Peptide Therapeutics Pipeline Database provides online access to Peptide Therapeutics on the market and in research & development. The peptide segment database contains about 900 files. Each project (file) is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic peptides is intuitive. Data sets of interest can be printed and exported in Word or Excel format. Projects are being updated continuously by passive and active searches. Information from press releases is entered on a daily basis. Active searches for targets, indications, company pipelines, scientific congresses, corporate releases, publications and in other sources are conducted on a rotating, re
Published Date: Nov 2014
Published By: La Merie Publishing

Price: $1016
Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders
This business report from July 2014 is based on the identification, description and assessment of all relevant stakeholders in the field of botulinum neurotoxins. The report analyzes the existing product portfolios in regulated and less regulated markets, commercial information, and measures to maintain sales and market shares by upside indications and life cycle management measures. The report addresses the new wave of botulinum neurotoxin product candidates in development, such as biosimilars and biosuperior botulinum neurotoxins. Special emphasis is put in the report on improvements by pharmaceutical technologies, such as liquid protein formulations and transdermal drug delivery technologies. The significance of recombinant DNA technology is discussed regarding botulinum neurotoxin e
Published Date: Jul 2014
Published By: La Merie Publishing

Price: $2656
Competitor Analysis: Cancer Vaccines
The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Projects are listed according to their main antigenic constituents: peptides, recombinant proteins, idiotype antibody, DNA (plasmid, expression vector), RNA, virus-like particles (VLP), dendritic cells, tumor cells (tumor cell lines), microorganism-based and others. Of the 140 clinical stage cancer vaccines, thr
Published Date: Mar 2014
Published By: La Merie Publishing

Price: $1112
Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014
Biosimilar and Biosuperior Therapeutic Antibodies 2014 The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014 provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of March 2014. Marketed antibodies are attractive for companies to create next generation variants and  biosimilar copies because they represent clinically and commercially validated products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug conjugates or bispecific molecules as well as the expiration of patents stimulate the discovery and development of biosimilar and biosuperior/biobetter molecules. Total s
Published Date: Mar 2014
Published By: La Merie Publishing

Price: $1523
Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis
The report entitled „Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis“ published in January 2014 is based on the evaluation of more than 90 companies. The report analyzes established and new antibody-drug conjugate (ADC) technologies, business activities and opportunities and assesses more than 100 ADC development and research programs. The commercial value of ADC technologies, ADC products and ADC product candidates is described and valued by means of sales, product prices, company market capitalization, initial public offerings, venture capital and private equity financing, infrastructure investments and financial deal terms. Business deal activities in form of acquisitions, licensing and collaboration agreements and joint ventures between
Published Date: Jan 2014
Published By: La Merie Publishing

Price: $2873
The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry
A  comparative analysis and assessment of TCR technologies, pipelines and  companies from an industry perspective Therapeutic monoclonal antibodies have become an  increasingly successful treatment modality with sales of US$ 65 bln in the year  2012 and with an average (continuous) annual growth rate from 2006 to 2012 of  18.9%. While antibody technologies are steadily evolving, the spectrum of  druggable targets for monoclonal antibodies has remained limited to  extracellular antigens, albeit including proteins, carbohydrates and  glycolipids.   Access to druggable, IP-protected and validated new targets  is a major bottleneck in the biopharmaceutical industry. Technologies which can  deliver both new targets and the correspondi
Published Date: Oct 2013
Published By: La Merie Publishing

Price: $1919
Protein Target & Pipeline Database: 1-Year Subscription
Product description Subscription to La Merie Publishing’s proprietary Protein Database provides online access to information about more than 1900 project entries for therapeutic proteins on the market and in research & development. Pre-established and free search functions allow to identify proteins according to their Target (e.g. Factor VIII, G-CSF, FSH) Pipelines (selected by target, therapeutic area, company) Sales (for marketed proteins) R&D Phase (clinical phases, market, preclinical) Territory (countrywise) Therapeutic Area (e.g. infectious, oncology, gastrointestinal) Drug Code/Name (for individual molecules) Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic proteins is intu
Published Date: Jul 2013
Published By: La Merie Publishing

Price: $1588
Competitor Analysis ErbB / Her Receptor Antagonists
  The present Competitive Intelligence Report about antagonists of the ErbB/Her receptor pathway provides a competitor evaluation in the field of ErbB1 (EGF-R), ErbB2 (Her), ErbB3 (Her) and ErbB4 (Her4) receptor targeting molecules for treatment of cancer as of July 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.   Targeted treatment of EGF-R and Her2-positive cancers with target specific antibodies has become an example of successful personalized medicine. The commercial success of small molecule ErbB/Her receptor tyrosine kinase inhibitors and
Published Date: Jul 2013
Published By: La Merie Publishing

Price: $853
Recombinant Coagulation Factors 2013 - The Race to Market and for Market Shares: A Technology & Pipeline Assessment and Corporate Benchmarking Analysis
A Technology & Pipeline Assessment and Corporate Benchmarking Analysis The report “Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares: Technology & Pipeline Assessment and Corporate Benchmarking Analysis” of June 2013 describes a market forecast based on growth of historical sales of recombinant coagulation factors. The report evaluates reasons for failures of novel recombinant coagulation factors and provides detailed profiles of active recombinant coagulation factors in clinical development. Preclinical projects are valued on the basis of the underlying technologies. Emerging alternative therapeutic approaches are described and assessed.  The detailed target pipeline assessments put emphasis on the competitive situation re
Published Date: Jun 2013
Published By: La Merie Publishing

Price: $2767
Flat-Rate Access to R&D Database & Reports from La Merie Publishing
A one-year subscription to this product provides 24/7 online access to both services from La Merie Publishing with a 30% discount on the list prices for all license types. Internet access is the only prerequisite for this service.
Published Date: May 2013
Published By: La Merie Publishing

Price: $8470
Competitor Analysis: Coagulation Factors
Competitor Analysis: Coagulation Factors Product description The Competitive Intelligence Report Coagulation Factors provides a competitor analysis of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of May 2013. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Global sales of the six major recombinant branded products of coagulation factors VIII, IX and VIIa in 20012 were US$ 7.2 bln. This attractive market size and the soon beginning expiration of basic paten
Published Date: May 2013
Published By: La Merie Publishing

Price: $784
Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets: Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) G-CSF & GM-CSF Thrombopoietin & Thrombopoiesis Stimulating Agents Interferon Insulin Coagulation Factors Human Growth Hormone (hGH) FSH, hCG and LH: Therapeutic Proteins for Assisted Reproductive Technology (ART) Thrombolytics & Fibrinolytics Enzyme Replac
Published Date: May 2013
Published By: La Merie Publishing

Price: $2092
Competitor Analysis: Antibody-Drug Conjugates (ADC)
Product description The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The emerging therapeutic class of antibody-drug conjugates (ADC) is coming of age. Two approved and marketed ADC drugs utilizing each one of the two major technologies (auristatin and maytansin derivatives) have paved the
Published Date: Apr 2013
Published By: La Merie Publishing

Price: $785
Influence of Antibody Attributes on Clinical Success - A Technology and Coporate Benchmark Analysis
The analytical report „Influence of Antibody Attributes on Clinical Success – A Technology and Coporate Benchmark Analysis“ evaluates the impact of a number of antibody attributes on the success rate of antibodies in clinical development. Among the antibody attributes studied  in this investigation are antibody generation technology, animal species of the parental antibody, antibody format, immunoglobulin class and isotype, target, and therapeutic area. Information from more than 500 naked recombinant monoclonal antibodies was used for this research. Antibodies which failed in clinical development were further analyzed for the reason of failure and phase in which they were discontinued. Biotech and pharmaceutical companies with a significant R&D portfolio of ther
Published Date: Mar 2013
Published By: La Merie Publishing

Price: $1203
Antibody Technologies and Attrition Rates - an industry analysis 2013
The report “Antibody Technologies and Attrition Rates – an industry analysis 2013” is based on the identification of the antibody generation technologies of 504 naked antibodies in clinical or market stages. Information was retrieved from scientific and corporate publications as well as from patent and legal literature. The report provides descriptive statistics of the 504 naked antibodies and their status during the study period of January 1, 2013 to February 28, 2013. The antibodies are categorized as active during the study period or discontinued during or before the study period. Attrition rates were calculated across a number of variables.  Descriptive statistics of the 504 naked antibodies include the following variables: Unique antibody identifie
Published Date: Mar 2013
Published By: La Merie Publishing

Price: $2781
Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists
Toll-Like Receptor (TLR) Agonists & Antagonists Product description The Competitive Intelligence Report Toll-Like Receptor (TLR) Agonists & Antagonists provides a competitor analysis in the development pipeline of novel small molecules, proteins, DNA, RNA and vaccines targeting the toll-like receptors (TLR) for treatment or prevention of cancer, infectious diseases, sepsis and allergy as of October 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate
Published Date: Dec 2012
Published By: La Merie Publishing

Price: $910
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012
This report “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012” published in March 2012 provides a compilation of business, commercial, clinical and scientific information about GLP-1 receptor agonists. A comprehensive analysis of the state of the art and key trends guides the reader through this emerging antidiabetic drug class.
Published Date: Mar 2012
Published By: La Merie Publishing

Price: $2524
Competitor Analysis: Anti-Infective Antibodies
Competitor Analysis: Anti-Infective Antibodies Product description The present Competitive Intelligence Report about Anti-Infective Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies and human plasma-derived immunoglobulins and hyperimmunes for post-exposure prophylaxis and treatment of infectious diseases as of November 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The emergence of antibiotic resistant microorganisms, lethal viruses and the threat of engineered microorganism ha
Published Date: Nov 2011
Published By: La Merie Publishing

Price: $1029
Coagulation Factors 2011. Who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis
Coagulation Factors 2011 who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis Product description The report Coagulation Factors 2011 who does meet the market needs?  A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis provides a description, evaluation and assessment of the recombinant coagulation factor R&D pipelines as of October 2011. The authors analyze and assess the target pipeline for each of the coagulation factors for haemophilia and work out the target profiles of development projects. A market research study was conducted to challenge industrys target profiles and evaluate the sensitivity for pricing. The report is built upon primary and secondary search for information and use of a propri
Published Date: Oct 2011
Published By: La Merie Publishing

Price: $3087
Vaccine Pipeline Database: 1-Year Subscription
Vaccine Pipeline Database: 1-Year Subscription Product description Subscription to La Merie’s proprietary Vaccine Pipeline Database provides online access to more than 1,200 project entries for prophylactic and therapeutic vaccines on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of the R&D database of vaccines is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed.  The projects can be segmented into Territories, Therapeutic Areas and R&D Phases. An advanced search function allows to combine search
Published Date: Oct 2011
Published By: La Merie Publishing

Price: $1287
Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis Product description This report “Antibody-Drug Conjugates 2011 – real breakthrough still to come: A Technology, Stakeholder and R&D Pipeline Analysis” published in September 2011 provides the most complete compilation of information about antibody-drug conjugate (ADC) companies, technologies and products in R&D. A comprehensive analysis of the state of the art and key trends guides the reader through this complex subject. Stakeholders in the field of antibody-drug conjugates are analysed and their contribution to the growth ADC technology and products is assessed. A critical appraisal of the clinical results of active and discontinued
Published Date: Sep 2011
Published By: La Merie Publishing

Price: $2524
Competitor Analysis: Targeted Therapy of Hepatitis C
The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV RNA up to 6 months after therapy is concluded. To increase efficiency of interferon treatm
Published Date: Aug 2011
Published By: La Merie Publishing

Price: $772
RNA Therapeutics Pipeline Database: 1-Year Subscription
RNA Therapeutics Pipeline Database: 1-Year Subscription Product description Subscription to La Merie’s proprietary RNA Therapeutics Pipeline Database provides online access to RNA Therapeutics on the market and in research & development. RNA Therapeutics include the classes of antisense, aptamers, small interfering RNA (siRNA)/RNA interference (RNAi) or Locked Nucleic Acid (LNA) RNA. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic proteins is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously by passive and active searches. Information from press releases is entered on a daily basis. Active searches for targets, indications, company
Published Date: Mar 2011
Published By: La Merie Publishing

Price: $772
Therapeutic Protein Pipeline Database: 1-Year Subscription
Subscription to La Merie’s proprietary Therapeutic Protein Pipeline Database provides online access to more than 1,700 project entries for therapeutic proteins on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic proteins is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously by passive and active searches. Information from press releases is entered on a daily basis. Active searches for targets, indications, company pipelines, scientific congresses, corporate releases, publications and in other sources is conducted on a rotating, regular basis. The R&D history of each project with online ref
Published Date: Feb 2011
Published By: La Merie Publishing

Price: $1544
Antibody Pipeline Database: 1-Year Subscription
Subscription to La Meries proprietary Antibody Pipeline Database provides online access to more than 1,600 project entries for therapeutic antibodies on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic antibodies is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major products are provided. The projects can be segmented into Territories, Therapeutic Areas and R&D Phases. An advanced search function allows to combine search parameters. A scroll down menu for predefined
Published Date: Nov 2010
Published By: La Merie Publishing

Price: $1544
R&D Drug Pipeline Database: 2-Months Subscription
Subscription to La Meries proprietary R&D Drug Pipeline Database provides online access to more than 12,000 project entries in all therapeutic areas and product categories. Each project is specified for its Target or Mechanism of Action, Product Category, Therapeutic Area, indication and R&D Phase. Use of the R&D database of marketed and investigational drugs is intuitive.
Published Date: Aug 2010
Published By: La Merie Publishing

Price: $2573
R&D Drug Pipeline Database: 1-Year Subscription
Subscription to La Merie Publishing’s proprietary R&D Drug Pieline Database provides 24/7 online access to information about more than 21,000 project entries (files) for therapeutic drugs on the market and on investigational drug candidates in research & development.
Published Date: Aug 2010
Published By: La Merie Publishing

Price: $6600
Flat-Rate Subscription to La Merie Publishing Reports & News Services
After purchase of the Flat-Rate Subscription to La Merie Publishing Reports & News Services, credentials to access a dedicated server account with the report archive will be provided by e-mail. New issues of R&D Pipeline News and the R&D and Business Tracking Services will be delivered by e-mail, old issues are archived in the dedicated server account.
Published Date: Jun 2010
Published By: La Merie Publishing

Price: $5500
Oncology Pipeline Database: 1-Year Subscription
Subscription to La Merie’s proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category and R&D Phase. Use of the R&D database of cancer drugs is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously.
Published Date: May 2010
Published By: La Merie Publishing

Price: $2316
Oncology Pipeline Database: 6-Month Subscription
Subscription to La Merie’s proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category and R&D Phase. Use of the R&D database of cancer drugs is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously.
Published Date: Feb 2010
Published By: La Merie Publishing

Price: $1544

Back To Top